<?xml version='1.0' encoding='utf-8'?>
<document id="31609432"><sentence text="Development and Validation of HPLC and HPTLC Methods for Therapeutic Drug Monitoring of Capecitabine in Colorectal Cancer Patients."><entity charOffset="88-100" id="DDI-PubMed.31609432.s1.e0" text="Capecitabine" /></sentence><sentence text="Capecitabine is a prodrug of 5-fluorouracil, employed as a monotherapy or combination chemotherapy agent for treatment of colorectal cancer"><entity charOffset="0-12" id="DDI-PubMed.31609432.s2.e0" text="Capecitabine" /><entity charOffset="29-43" id="DDI-PubMed.31609432.s2.e1" text="5-fluorouracil" /><pair ddi="false" e1="DDI-PubMed.31609432.s2.e0" e2="DDI-PubMed.31609432.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31609432.s2.e0" e2="DDI-PubMed.31609432.s2.e1" /></sentence><sentence text=" Combination therapy of capecitabine consists of oxaliplatin, and hence, it becomes essential to determine that co-administration does not affect its metabolism"><entity charOffset="24-36" id="DDI-PubMed.31609432.s3.e0" text="capecitabine" /><entity charOffset="49-60" id="DDI-PubMed.31609432.s3.e1" text="oxaliplatin" /><pair ddi="false" e1="DDI-PubMed.31609432.s3.e0" e2="DDI-PubMed.31609432.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31609432.s3.e0" e2="DDI-PubMed.31609432.s3.e1" /></sentence><sentence text=" High-performance liquid chromatography and high-performance thin-layer chromatography methods were developed and validated to determine the plasma concentration of capecitabine"><entity charOffset="165-177" id="DDI-PubMed.31609432.s4.e0" text="capecitabine" /></sentence><sentence text=" In this study, blood samples from 12 patients with colorectal cancer were collected and analyzed by both methods with a reference internal standard" /><sentence text=" Two groups consisting of six patients each were formed: the first group was treated with capecitabine monotherapy, the second group with capecitabine + oxaliplatin combination therapy"><entity charOffset="90-102" id="DDI-PubMed.31609432.s6.e0" text="capecitabine" /><entity charOffset="138-164" id="DDI-PubMed.31609432.s6.e1" text="capecitabine + oxaliplatin" /><pair ddi="false" e1="DDI-PubMed.31609432.s6.e0" e2="DDI-PubMed.31609432.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31609432.s6.e0" e2="DDI-PubMed.31609432.s6.e1" /></sentence><sentence text=" The results of analysis from both the methods indicated that there is no significant drug-drug interaction" /><sentence text=" The co-administration of oxaliplatin did not affect the metabolism of capecitabine"><entity charOffset="26-37" id="DDI-PubMed.31609432.s8.e0" text="oxaliplatin" /><entity charOffset="71-83" id="DDI-PubMed.31609432.s8.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.31609432.s8.e0" e2="DDI-PubMed.31609432.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31609432.s8.e0" e2="DDI-PubMed.31609432.s8.e1" /></sentence><sentence text=" Both assay methods were compared for their sensitivity, robustness and specificity" /><sentence text=" It was found that both the assay methods were suitable for therapeutic drug monitoring of capecitabine"><entity charOffset="91-103" id="DDI-PubMed.31609432.s10.e0" text="capecitabine" /></sentence><sentence text="" /></document>